{"id":56472,"date":"2023-05-03T00:05:26","date_gmt":"2023-05-02T22:05:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/"},"modified":"2023-05-03T00:05:26","modified_gmt":"2023-05-02T22:05:26","slug":"reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/","title":{"rendered":"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023"},"content":{"rendered":"
\n

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc.<\/a> (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d \u201cour,\u201d \u201cus,\u201d or \u201cwe\u201d), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company\u2019s business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open.<\/p>\n

<\/a><\/p>\n

\nConference Call Information<\/b><\/p>\n

\nReata\u2019s management will host a conference call on May 10, 2023, at 8:30 am ET. The conference call will be accessible by dialing (833) 470-1428 (toll-free domestic) or (929) 526-1599 (international) using access code 283635. The webcast link is https:\/\/events.q4inc.com\/attendee\/647566363<\/a>.<\/p>\n

\nFirst quarter 2023 financial results to be discussed during the call will be included in an earnings press release that will be available on the company\u2019s website shortly before the call at https:\/\/www.reatapharma.com\/investors\/<\/a> and will be available for at least 12 months. The audio recording and webcast of the conference call will be accessible for at least 90 days after the event at https:\/\/www.reatapharma.com\/investors\/<\/a>.<\/p>\n

\nAbout Reata<\/b><\/p>\n

\nReata is a global, biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata\u2019s first product, SKYCLARYS\u2122 (omaveloxolone) has been approved by the FDA and is under review in Europe by the EMA. In addition, Reata is developing bardoxolone methyl (\u201cbardoxolone\u201d) for the treatment of patients with chronic kidney disease and cemdomespib for the treatment of patients with diabetic neuropathic pain.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation, our plans and objectives for the commercialization of SKYCLARYS and the timing thereof, our expectations regarding the size of the patient population for SKYCLARYS, and our plans to research, develop, and commercialize our other product candidates. You can identify forward-looking statements because they contain words such as \u201cbelieves,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201caims,\u201d \u201cplans,\u201d \u201cmodel,\u201d and \u201cexpects.\u201d Forward-looking statements are based on Reata\u2019s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the potential market size and the size of the patient population for SKYCLARYS and the market opportunities for SKYCLARYS; (ii) our ability to successfully build our commercial infrastructure to manufacture, market and sell SKYCLARYS, including the successful development and implementation of our sales and marketing campaigns for SKYCLARYS; (iii) the ability of our third-party suppliers and contract manufacturers to manufacture SKYCLARYS at the required quality and quantities and in compliance with applicable laws and regulations; and (iv) other factors set forth in Reata\u2019s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, under the caption \u201cRisk Factors.\u201d The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nReata Pharmaceuticals, Inc.
\n
(972) 865-2219
\n
https:\/\/www.reatapharma.com\/<\/a><\/p>\n

\nInvestor Relations & Media Relations:<\/b>
John Hunter ir@reatapharma.com<\/a>
Wendy Segal media@reatapharma.com<\/a>
https:\/\/www.reatapharma.com\/contact-us\/<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d \u201cour,\u201d \u201cus,\u201d or \u201cwe\u201d), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company\u2019s business operations … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56472","6":"format-standard","7":"category-industry"},"yoast_head":"\nReata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d \u201cour,\u201d \u201cus,\u201d or \u201cwe\u201d), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company\u2019s business operations ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T22:05:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230502006223\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023\",\"datePublished\":\"2023-05-02T22:05:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/\"},\"wordCount\":616,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006223\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/\",\"name\":\"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006223\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\",\"datePublished\":\"2023-05-02T22:05:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006223\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006223\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/","og_locale":"en_US","og_type":"article","og_title":"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 - Pharma Trend","og_description":"PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d \u201cour,\u201d \u201cus,\u201d or \u201cwe\u201d), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company\u2019s business operations ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-02T22:05:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230502006223\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023","datePublished":"2023-05-02T22:05:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/"},"wordCount":616,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502006223\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/","url":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/","name":"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502006223\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","datePublished":"2023-05-02T22:05:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230502006223\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230502006223\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-inc-to-report-first-quarter-2023-financial-results-and-to-provide-an-update-on-operational-progress-and-clinical-development-programs-on-may-10-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56472"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56472\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}